Evidence map›Paper›PMID 42370133›Full record

ArticleFrontiers in oncology2026

Combined SSTR2-targeted Analogue with

Carlen A Yuen, Mahbod Jafarvand, David O Kamson, Eleanor Chu, Jennifer E Soun, William H Yong, Frank P Hsu, Hansen Bow, Michelle Zheng, Shyam M Srinivas

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carlen A YuenDepartment of Neurology, Division of Neuro-oncology, University of California, Irvine, Irvine, CA, United States.
Mahbod JafarvandDepartment of Radiology, Division of Nuclear Medicine, University of California, Irvine, Irvine, CA, United States.
David O KamsonThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States.
Eleanor ChuChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, United States.
Jennifer E SounChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, United States.
William H YongDepartment of Pathology, Division of Neuropathology, University of California, Irvine, Irvine, CA, United States.
Frank P HsuChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, United States.
Hansen BowChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, United States.
Michelle ZhengUC Irvine Charlie Dunlop School of Biological Sciences, Irvine, Irvine, CA, United States.
Shyam M SrinivasDepartment of Radiology, Division of Nuclear Medicine, University of California, Irvine, Irvine, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meningiomas are the most common primary intracranial tumor in adults. Beyond surgery and radiation, no standard of care therapy exists. Meningiomas overexpress somatostatin receptor 2 (SSTR2), providing the rationale for somatostatin analogue-based therapies, including octreotide. The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate. For this reason, novel therapies have emerged for the treatment of refractory meningiomas, including somatostatin receptor targeted radionuclide therapy. However, preliminary results with refractory meningiomas treated with single agent

Indexed as

177Lu-DOTATATEmeningiomaoctreotidepeptide receptor radionuclide therapy (PRRT)somatostatin receptor type 2 (SSTR2)

Identifiers

PMID42370133
PMCPMC13293792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.